Asaleo Care Limited Overview
Asaleo Care was Australasia's leading locally manufactured personal care and hygiene company. It combined owned heritage brands such as Libra (feminine care), Purex, Sorbent and Handee (tissue in New Zealand and the Pacific), Viti and Orchid (Pacific Islands) and TOM Organic (organic feminine care, acquired 2021) with exclusive Australasian licences to Essity's global brands TENA (incontinence) and Tork (professional hygiene). After it sold the Australian consumer tissue business to Solaris Paper in March 2019, Asaleo repositioned toward higher-margin, less capital-intensive categories: feminine care, incontinence and away-from-home hygiene systems. It served supermarkets and pharmacy retail through its Retail segment and served aged care, hospitals and facility operators through its B2B segment. Its strategic logic always depended on Essity, which was its 36.2% shareholder, technology licensor and trademark licensor. Essity took the company private in 2021 at an A$855m enterprise value, ending seven years as a listed entity.
What the company did. In its last years as a listed company, Asaleo described itself as a personal care and hygiene company that marketed, manufactured, distributed and sold personal care and hygiene products across Australia, New Zealand and the Pacific Islands. Its final ASX release named Libra, TENA, Tork, Viti and Orchid as its portfolio brands. It noted that it owned the Purex, Sorbent and Handee brands only in New Zealand and the Pacific Islands, because the Australian rights had passed to Solaris Paper in 2019 (Asaleo ASX release, 1 Jul 2021).
Business model. Asaleo was a vertically integrated converter and brand owner. It manufactured tissue (from parent reels at Kawerau, New Zealand), feminine care products (Australia; it was the only Australian manufacturer of feminine care products, per TOM Organic founder commentary, Inside FMCG, Dec 2020) and Pacific Islands tissue (Fiji). It then marketed under owned and licensed brands. The revenue model was almost entirely product sales. A smaller but strategically important stream came from B2B dispenser-based "Hero Systems" under Tork, which locks in consumable refill sales over the life of the installed dispenser base (InClean, H1 FY2019). The company had no material subscription or licensing income. It was itself a licensee, paying for the TENA and Tork trademarks and Essity technology under a Trade Mark and Technology License Agreement that was extended to 2027 in 2019 (InClean, H1 FY2019).
Value chain position. Asaleo sat midstream to downstream. It bought pulp (a globally priced, USD-denominated commodity) and energy, converted them into finished goods, and sold to grocery retailers (Woolworths, Coles, Foodstuffs and Woolworths NZ, which are retailer names from analyst recall), distributors and institutional buyers. Pulp, electricity and the AUD/USD exchange rate were the dominant cost swing factors (Morningstar, Jul 2018; Kalkine, Apr 2017).
Customer types and end-markets.
(Segment structure and customer list per Investing.com and PitchBook company descriptions, and Asaleo results commentary.)
Independent characterisation. Asaleo was a structurally sub-scale regional consumer staples business with good brands but limited pricing power. It was squeezed between two forces. On one side were global commodity inputs. On the other were Australia's concentrated grocery retail duopoly and aggressive private-label and import competition, notably APP-backed Solaris Paper in tissue and Kimberly-Clark in feminine care. The 2018 profit warnings showed this vulnerability: input costs rose about A$10m in one half, competitors did not follow Asaleo's price increases, and volumes fell (Morningstar, Jul 2018). The 2018–19 strategic review correctly identified tissue as the weakest economic franchise and exited it in Australia. The remaining portfolio, built around feminine care, incontinence (which carries a structural ageing tailwind) and Tork systems, was worth more to Essity as an owner with global R&D, procurement and brand scale than as a standalone listed entity. That is why the endgame was a take-private by its licensor.
Strategy
Stated strategy themes (Asaleo, 2019–2021):
-
To become "the leader in personal care and hygiene in Australasia" by investing in brands and putting customers and consumers first (Takla, H1 FY2019, InClean).
-
To concentrate on higher-margin, less capital-intensive Personal Care and B2B businesses (Takla on the tissue sale, Motley Fool, Apr 2019).
-
To enter higher-growth "better-for-you" personal care sub-categories, using TOM Organic's digital and e-commerce capabilities (Inside FMCG, Dec 2020).
-
Earlier (FY2015) pillars under Diplaris: product innovation and differentiation, range and coverage, distribution innovation, and cost reduction and efficiency (InClean).
Medium-term targets:
-
FY2021: revenue growth of 5–7%, driven by feminine care, retail incontinence and B2B incontinence healthcare (Kalkine, May 2021).
-
FY2022 (as reported by Kalkine, likely from scheme booklet projections): revenue of A$462.2–471.0m and EBITDA of A$99.0–102.3m (~10% growth).
Successor strategy (Essity AustralAsia):
-
Integration into Essity's global category model.
-
The Modibodi period-underwear acquisition, extending the feminine care adjacency started with TOM Organic (Mumbrella).
-
Decarbonisation at Kawerau through geothermal steam (Essity, Mar 2025).
Products & Services
Retail segment
| Brand | Category | Description / capabilities | Target customer | Ownership | Status post-2021 |
|---|---|---|---|---|---|
| Libra | Feminine care | Pads, liners, tampons; Australia's leading feminine care brand; manufactured locally in Australia | Women 12–50, grocery and pharmacy | Owned in Australasia (Essity's global equivalent is Libresse/Bodyform) | Core Essity AustralAsia brand (Mumbrella) |
| TOM Organic | Organic feminine care | Certified-organic cotton tampons, pads, liners, period briefs, menstrual cups; founded 2009 by Aimee Marks; strong e-commerce; Australian Organic awards 2014, 2018, 2019 | Sustainability-oriented consumers | Acquired Jan 2021 for A$12.75m; expected first-year net revenue >A$11m | Retained under Essity (Mumbrella) |
| TENA (retail) | Adult incontinence | Pads, pants, men's range for light-to-heavy incontinence | Ageing consumers, grocery and pharmacy | Licensed from Essity until 2021; now Essity-owned locally | Core |
| Purex | Toilet tissue | Premium toilet tissue | NZ and Pacific households | Owned in NZ/Pacific only; Australian rights sold to Solaris 2019 | Essity in NZ |
| Sorbent | Toilet and facial tissue, flushable wipes | Mainstream tissue brand | NZ and Pacific households | Owned in NZ/Pacific only | Essity in NZ |
| Handee / Handee Ultra | Paper towel | Kitchen towel | NZ and Pacific households | Owned in NZ/Pacific only | Essity in NZ |
| Deeko | Serviettes and disposable tableware | Party and tableware | Households | Australian business sold to Solaris 2019; listed in Essity's 2021 brand list | Unclear (n/d) |
| Treasures | Baby nappies and wipes | Infant care | NZ parents | Owned (NZ) | — |
| Viti | Toilet tissue | Pacific value tissue | Fiji and Pacific Islands | Owned | Essity |
| Orchid | Hygiene/tissue | Pacific hygiene brand | Fiji and Pacific Islands | Owned | Essity |
B2B segment
| Brand / offering | Category | Description / capabilities | Target customer | Ownership |
|---|---|---|---|---|
| TENA healthcare | Institutional incontinence | Continence products plus clinical services and continence assessment support for aged care providers | Residential aged care, hospitals, in-home care | Licensed (now Essity) |
| Tork Professional Hygiene | Away-from-home hygiene | Washroom towels, toilet tissue, soap, wipers, dispensers | Offices, schools, restaurants, shopping centres, airports, industry, healthcare | Licensed (now Essity) |
| Tork "Hero Systems" | Proprietary dispenser systems | High-margin closed dispenser systems that lock in refills | Facility managers, distributors | Licensed; called out as a growth driver (InClean, H1 FY2019) |
Pricing models: list-price plus promotional trade spend in Retail, and contract and distributor pricing in B2B. Specific pricing was not publicly disclosed. Launch dates and versions of individual SKUs were not disclosed in the sources reviewed.
Financial Narrative
Income statement
Notes:
-
FY2016 revenue fell 2.6% YoY and underlying NPAT fell 15.2% (Kalkine, Apr 2017).
-
FY2015 underlying NPAT was A$76.1m and statutory NPAT A$75.6m (InClean).
-
FY2018 underlying EBITDA guidance was cut to A$80–85m from A$113–119m (Morningstar, Jul 2018). The final FY2018 outcome is n/d.
-
FY2019 underlying EBITDA of A$82.4m was +1.1% as reported, but −11% excluding the AASB 16 lease accounting benefit (InClean). Statutory NPAT A$22.1m.
-
FY2020 sales of A$419m and underlying EBITDA of A$89m are per Essity. Revenue of A$420.02m is per Kalkine/MarketBeat. Asaleo's own guidance was the upper end of A$84–87m (InClean, Aug 2020), so the A$89m figure may reflect a different definition (for example, including TOM Organic transaction adjustments). This is an unreconciled discrepancy.
-
EPS (basic and diluted), gross profit, operating income and pre-tax income for FY2016–FY2020: n/d.
-
Revenue CAGR FY2019–FY2020: +2.4% (single year). A five-year CAGR is not computable because FY2016–FY2018 revenue includes the divested Australian tissue business and is n/d on a like-for-like basis.
Half-year income data: notes and sources
Sources: Kalkine (H1 FY2017, H1 FY2019); Market Matters (H1 FY2018); InClean (H1 FY2020). H1 FY2019 underlying revenue was A$202.0m (+2.2%), EBITDA was down 8.2% and EBIT down 21.8%. InClean cites the prior-year comparative for H1 FY2020 NPAT as A$7.8m, against Kalkine's A$7.3m for H1 FY2019. This is a minor source discrepancy, likely statutory versus continuing operations.
Balance sheet and leverage
-
Net debt at deal (implied EV minus equity): A$855m − A$760m = ~A$95m, derived from Essity, Feb 2021.
-
Book value per share: ~A$0.36 (MarketBeat). Implied book equity ≈ A$196m (derived; 543.25m shares × A$0.36).
-
Debt/equity: 88.71% (MarketBeat; period not stated).
-
Current ratio: 1.74; quick ratio: 0.68 (MarketBeat; period not stated).
-
Total assets, cash, short/long-term debt split, goodwill and intangibles, and working capital for FY2016–FY2020: n/d.
Cash flow and capital management
-
FY2017 free cash flow guidance: A$85–95m (Kalkine, Apr 2017).
-
Stated capital management policy (2014–2017): pay out 70–80% of statutory NPAT as dividends, with leverage held within 1.5x–2.5x EBITDA (Kalkine).
-
That policy was breached in 2018, when leverage reached 3.25x, and dividends were cut. No interim dividend was declared in H1 FY2020. FY2019 final dividend was 2c (unfranked); FY2020 final dividend was 3c (fully franked, paid 31 March 2021); a special 2c fully franked dividend was paid 21 June 2021.
-
Share buybacks: an on-market buyback was conducted around 2017–2018 (details n/d).
-
Operating cash flow and capex series: n/d.
Ratios
FY2016 ratios per Kalkine. ROA, interest coverage, asset turnover and cash conversion cycle: n/d.
Commentary
The five-year arc falls into three phases.
Phase 1 (FY2014–FY2016): post-IPO deterioration. Underlying NPAT peaked at A$76.1m in FY2015, then fell 15.2% in FY2016. A weaker AUD inflated USD-denominated pulp and imported-goods costs by about A$15m, and Personal Care trading weakened in the first half.
Phase 2 (FY2017–FY2018): the crisis. H1 FY2017 still showed modest growth, but by mid-2018 pulp and electricity inflation of about A$10m in a half, combined with competitors refusing to follow Asaleo's price rises, cut underlying EBITDA 24% and forced a ~30% guidance downgrade. Leverage climbed to 3.25x, outside the stated 1.5x–2.5x band.
Phase 3 (FY2019–FY2020): reset. The A$180m tissue divestment repaid debt, bringing leverage to about 2.1x and facilities down to A$250m. It also lifted the group's EBITDA margin to roughly 20–21%, against an Australian tissue business whose margins had been eroding. COVID-19 panic buying in H1 FY2020 then delivered an outsized half, with NPAT up about 2.4x.
The key inflection is that the post-divestment group had lower absolute earnings, roughly A$82–89m of EBITDA against about A$130m in FY2016, but better quality: higher margin, lower capital intensity and better growth exposure in incontinence and feminine care. Essity's A$855m enterprise value equated to roughly 9.6x FY2020 underlying EBITDA (derived: 855 / 89).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key brands |
|---|---|---|
Retail | Feminine care, retail incontinence, NZ/Pacific consumer tissue, NZ baby care, organic personal care (from 2021) | Libra, TENA (retail), Purex/Sorbent/Handee (NZ and Pacific), Treasures (NZ baby), Viti, Orchid, TOM Organic |
B2B | TENA incontinence healthcare (aged care, hospitals, in-home care); Tork professional hygiene (washroom systems, dispensers, wipers) | TENA, Tork |
Segment revenue (AUD Mn)
| Segment revenue (AUD Mn) | FY2019 | FY2020 |
|---|---|---|
Retail revenue | 198.6 | — |
B2B revenue | 221.6 | — |
Group total revenue | 410.3 | 420.0 |
Revenue by Segment
| Segment metric (AUD Mn) | H1 FY2019 | H1 FY2020 |
|---|---|---|
Retail revenue | 95.5 | 103.6 |
Retail EBITDA | 18.6 | 25.0 |
B2B revenue | 106.4 | 111.3 |
B2B EBITDA | 20.8 | 24.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment EBITDA margin (%)
| Segment EBITDA margin (%) | H1 FY2019 | H1 FY2020 |
|---|---|---|
Retail | 19.5 | 24.1 |
B2B | 19.5 | 21.9 |
Income Statement and Per-Share Data
| Metric | FY2016 | FY2019 | FY2020 |
|---|---|---|---|
Revenue (AUD Mn) | — | 410.3 | 420.0 |
Underlying EBITDA (AUD Mn) | 130.7 | 82.4 | 89.0 |
Underlying NPAT (AUD Mn) | 64.6 | — | — |
Statutory NPAT (AUD Mn) | — | 22.1 | — |
Dividends per share – final (AUD cents) | — | 2.0 | 3.0 |
Underlying EBITDA margin (%) | — | 20.1 | 21.2 |
Income Statement
| Metric | H1 FY2017 | H1 FY2018 | H1 FY2019 | H1 FY2020 |
|---|---|---|---|---|
Revenue (AUD Mn) | — | — | 202.0 | — |
Underlying EBITDA (AUD Mn) | 60.9 | 46.3 | 39.4 | 49.4 |
Underlying EBIT (AUD Mn) | — | — | 27.2 | — |
Statutory NPAT (AUD Mn) | 27.7 | — | 7.3 | 18.8 |
Financial Ratios (x) and Key Financials
| Metric | FY2018 | Mid-2019 |
|---|---|---|
Leverage ratio net debt/EBITDA (x) | 3.25 | 2.1 |
Total debt facilities (AUD Mn) | — | 250 |
Returns & Leverage Ratios (%)
| Ratio | FY2016 |
|---|---|
ROE (%) | 21 |
ROIC (%) | 12 |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY2019 | FY2020 |
|---|---|---|
Group total | 410.3 | 420.0 |
Segment Overview — Retail – feminine care
| Segment | Australia | New Zealand | Fiji / Pacific |
|---|---|---|---|
Retail – feminine care (Libra, TOM) | Primary market; local manufacture | Yes | Yes |
Retail – incontinence (TENA) | Yes | Yes | Limited |
Retail – consumer tissue | Exited Mar 2019 | Purex, Sorbent, Handee | Viti, Orchid, Sorbent |
Retail – baby (Treasures) | — | Yes (only category not growing at double digits in H1 FY2020) | — |
B2B – TENA healthcare | Yes | Yes | — |
B2B – Tork | Yes | Yes | — |
Share Price
| Price reference (AUD/share) | 2014 | 2017 | 2018 | 2020 | 2021 |
|---|---|---|---|---|---|
Reference price | 1.65 | 1.63 | 0.84 | 1.34 | 1.40 |
Dividend (AUD cents)
| Dividend (AUD cents) | FY2019 final | FY2020 final | 2021 special |
|---|---|---|---|
Dividend per share | 2.0 | 3.0 | 2.0 |
Analyst Conclusions
Guidance (final, from scheme-era disclosures):
-
FY2021 revenue growth of 5–7%.
-
FY2022 revenue of A$462–471m and EBITDA of A$99–102m.
-
These are not trackable, because results have been consolidated into Essity since July 2021.
Bull case (as at exit):
-
The repositioned mix (feminine care, incontinence, Tork) carried ~21% margins with structural demand tailwinds.
-
The balance sheet was repaired: net debt about A$95m against about A$89m EBITDA.
-
The TOM Organic and e-commerce platform offered growth in premium sub-categories.
Bear case (as at exit):
-
Absolute earnings stayed about 30% below FY2016 levels, and pricing power was weak.
-
Licence dependence capped strategic independence.
-
H1 FY2020 was flattered by panic buying, which was expected to unwind.
Monitorables, next 12 months (successor entity):
-
Essity's Asia/Pacific segment commentary.
-
Decarbonisation at Kawerau.
-
Performance of Libra, TOM Organic and Modibodi in the region.
-
Australian aged-care funding reforms affecting TENA healthcare.
Analyst verdict:
Asaleo Care's seven-year listed life is a case study in the limits of a sub-scale regional consumer staples business that depended on a global licensor. Its 2014 IPO packaged excellent local brands with exclusive rights to TENA and Tork, but the equity story assumed stable input costs and rational competition. Neither held. A weaker Australian dollar in FY2016 and a pulp and energy spike in 2018 exposed weak pricing power: when Asaleo raised prices, competitors held theirs and took volume. Two profit warnings within eight months and leverage of 3.25x forced a strategic reset. That reset was well executed. Selling the Australian tissue business to Solaris Paper for A$180m, about 10% above book, eliminated the most commoditised, capital-intensive operation, cut leverage to about 2.1x and left a business earning roughly 20–21% EBITDA margins in feminine care, incontinence and professional hygiene. The TOM Organic acquisition showed sensible portfolio direction into premium, sustainable sub-categories. The reset also clarified who the natural owner was. Essity owned the trademarks and technology, already held 36.2%, and could extract procurement and R&D synergies unavailable to minority holders. Its A$1.40 offer, about 9.6x FY2020 EBITDA and roughly 2x sales, was fair rather than generous. It also delivered a negative price return against the A$1.65 IPO, underscoring that public shareholders bore the cyclical pain while the strategic value accrued to the licensor. For investors today, Asaleo is a closed chapter: there is no security to own, and Essity AustralAsia's results are immaterial (about 2% of Essity's sales) and undisclosed. The lessons remain instructive. Licence-dependent listed subsidiaries tend to end in take-privates. Commodity-exposed staples need either scale or pricing power. And margin quality can matter more than earnings size.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
Sid Takla | CEO & Managing Director | ~2018–2021 | Led the 2018 strategic review, the tissue divestment, the TOM Organic acquisition and the Essity scheme |
Peter Diplaris | CEO & Managing Director | IPO (2014) to ~2017/2018 | Led the IPO and FY2015–FY2016 periods (InClean, FY2015) |
Major Shareholders
| Holder | Stake |
|---|---|
Essity (via Essity Group Holding BV) | 36.2% |
Other institutional and retail holders | 63.8% (individual top-10 holders n/d) |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Notes |
|---|---|---|
Kimberly-Clark Australia (Kotex, U by Kotex, Depend, Huggies, Kleenex) | Feminine care, incontinence, tissue, B2B (Kimberly-Clark Professional) | Libra's key rival |
Solaris Paper / Asia Pulp & Paper (Livi, Emporia; now Sorbent and Purex in Australia) | Tissue (NZ/Pacific overlap; Australia post-2019), B2B tissue | Aggressive pricing; acquired the Australian brands |
Procter & Gamble (Pampers, formerly Tampax/Whisper regionally) | Feminine care, baby | Global scale |
Edgewell (Carefree, Stayfree, o.b.) | Feminine care | Category challenger |
ABENA, Attends (Domtar/Ontex), Ontex | Institutional incontinence | Aged care tenders |
Private label (Woolworths, Coles, Aldi) | All retail categories | Price pressure |
Cottons (Corman) | Feminine care | Local challenger |
Modibodi, Thinx, JuJu (pre-2022) | Reusable period products | Disruptors |
Kimberly-Clark Professional, SCA rivals, Bunzl distribution | Tork away-from-home hygiene | B2B |
Nopal / Pacific regional tissue importers | Pacific tissue | Pacific |
Peer Comparison FY2020
| Metric | Asaleo Care (FY2020) | Kimberly-Clark (global) | Essity (group) |
|---|---|---|---|
Revenue | A$420m | n/d in sources reviewed | n/d in sources reviewed |
Underlying EBITDA margin | ~21% | — | — |
R&D intensity | Not disclosed (licensed) | — | — |
Recent Developments
Because Asaleo delisted in July 2021, there has been no issuer newsflow for the last 18 months (April 2025 – October 2026).
The 18-month window to October 2026 contains no further material developments specific to Essity AustralAsia that were identifiable in sources reviewed.



